TG4001 + Avelumab Phase 1b/2 results in HPV16+ R/M cancers Detailed data of the Phase 1b/2 trial presented at SITC 2020 Read the poster Access the webcast November 2020
Year: 2019
Transgene Reports First Promising Efficacy Results with TG4001 in Combination with Avelumab in HPV-Positive Cancer at ESMO 2019
20190930 PR TG4001 ESMO EN
Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic HPV16 positive cancers
Christophe Le Tourneau et al. ESMO 2019 Download the poster here Poster Presentation
Transgene Confirms the Timeline of its Clinical News Flow and Presents 2019 Half-Year Results
20190918-Transgene-H1-2019-RESULTS-EN
Transgene Receives Approval from the French Health Authority (ANSM) to Initiate Two Clinical Trials of its Lead myvac® Individualized Immunotherapy TG4050
20190916 PR ANSM TG4050 EN
Transgene Announces Upcoming Investor Meetings
20190829 PR financial Agenda
Transgene Provides an Update after the Interim Futility Analysis of the PHOCUS Study of Pexa-Vec in Liver Cancer
20190807 – Transgene Update EN
Transgene Provides Update on PHOCUS Study of Pexa-Vec in Liver Cancer Following Planned Interim Futility Analysis
20190802 PHOCUS Interim Analysis US
Transgene Receives MHRA Approval for a Clinical Trial of TG6002, a Next-generation Oncolytic Virus, Administered by Intrahepatic Artery Infusion in Patients with Colorectal Cancer with Liver Metastases
20190718 – TRANSGENE PR MHRA TG6002
Transgene Receives MHRA Approval for Lead myvac® Individualized Immunotherapy, TG4050, to Commence Clinical Development in HPV Negative Head and Neck Cancers in the UK
20190710 PR MHRA TG4050 EN